Obianda, Genrose .
HRN: 22-84-19 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/11/2023
METRONIDAZOLE 500MG (TAB)
05/11/2023
05/17/2023
ORAL
500 Mg
BID
S/P NSVD With RMLE And Repair Thickly Meconium Stained
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Guideline Not Available
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes